CDK5 and glioma: As shown in Figure 2I, patients with glioma with higher CDK5 expression had a worse prognosis in TCGA cohorts {hazards ratio (HR) 1.02, 95% CI [1.01-1.03], P = 0.001}, which was validated in GSE16011 cohorts {hazards ratio (HR) 1.30, 95% CI [1.01-1.69], P = 0.043}.